Amgen addresses safety concerns for its weight loss drug MariTide after new data suggests a potential 4% reduction in bone ...
A hidden tab in an Excel spreadsheet published nine months ago has wiped $12 billion off Amgen’s market cap. The tab ...
As an aside, in the tech space, see What’s Happening With Snap Stock? Although the recent Amgen update didn’t bode well with ...
Amgen Inc.'s stock dropped over 7% on Tuesday following revelations about bone density loss in early trials of its ...
On Tuesday, a tiny shred of data on Amgen’s lead obesity candidate — not yet verified — erased $12 billion in market value.
Recent health news highlights include Amgen addressing bone density concerns, AstraZeneca revising its financial outlook ...
(Reuters) -Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone ...
Wednesday said there is no association between administration of experimental weight loss drug MariTide and changes ...
Benzinga on MSN2d
Amgen Shares Drop 7% as Early Trial Data On Weight Loss Drug Raises Safety Concerns, Sparking Mixed Analyst ReactionsAmgen shares dropped over 7% Tuesday after bone density data from an early-stage trial of its weight loss drug, MariTide, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback